Ignite Creation Date:
2024-05-06 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05134129
Status:
UNKNOWN
Last Update Posted:
2021-11-24
First Post:
2021-08-10
Brief Title:
Correlation Between Targeted HbA1c Values and Prevention of Recurrent Cardiovascular Events in Type 2 Diabetes After PCI
Sponsor:
Shanghai 10th Peoples Hospital
Organization:
Shanghai 10th Peoples Hospital
Study Overview
Official Title:
Correlation Between Targeted Hemoglobin A1C Levels and Prevention of Recurrent Cardiovascular Events in Type 2 Diabetes After Coronary Intervention
Status:
UNKNOWN
Status Verified Date:
2021-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CATHEDRAL
Brief Summary:
Diabetes is a leading social and economic burden in the world It is the main reason of macrovascular disease incidence and mortality Prospective studies have demonstrated that high glycosylated hemoglobin HbA1C levels are associated with an increased risk of cardiovascular events in a population of diabetic patients without a history of coronary artery disease Further the predictive value of high preprocedural glycemia levels has been reported in diabetic patients undergoing percutaneous coronary intervention PCI The aim of the present study was to assess the predictive value of preprocedural HbA1C levels for cardiovascular complications in a large population of diabetic patients undergoing PCI with stent implantation Glycosylated hemoglobin HbA1c reflects the average blood sugar level in the past 2-3 months As glycosylated hemoglobin has been clinically tested and standardized internationally increasing evidence is recommended for routine monitoring in diabetes care The American Diabetes Association ADA suggested that in the treatment of diabetes blood sugar control should control HbA1c level below 65 Althoughthere is evidence that controlling blood glucose can reduce the incidence of microvascular complications in the past three trials intensive glycemic control did not significantly reduce adverse CV events in patients with onger duration of diabetesTherefore most primary and secondary prevention guidelines recommend HbA1c below 65 or 7 to prevent adverse cardiovascular outcomes in patients with diabetes mellitus The optimal target level of glycosylated hemoglobin is still hotly debated In addition there is still lack of evidence for the level of HbA1c in patients with major vascular disease history in secondary prevention of recurrence cardiovascular events
Therefore to explore and determine the optimal level of blood glucose control is the focus of controversy in preventing recurrence cardiovascular events in diabetic patients Investigator will combine epidemiology and metabolomics to study the effect of glycosylated hemoglobin on secondary cardiovascular events and further determine whether to strengthen hypoglycemic treatment after PCI
Therefore to explore and determine the optimal level of blood glucose control is the focus of controversy in preventing recurrence cardiovascular events in diabetic patients Investigator will combine epidemiology and metabolomics to study the effect of glycosylated hemoglobin on secondary cardiovascular events and further determine whether to strengthen hypoglycemic treatment after PCI
Detailed Description:
This is a longitudinal cohort study including retrospective study prospective study and nested case-control studyThe first cross-sectional survey was conducted in 2021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None